Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Newsnationnow

Published November 13, 2026

Ex-Navy pilot: Psychedelic drug saved me, could help other vets' PTSD - NewsNation

Read the full story at Newsnationnow

Health Secretary Robert F. Kennedy Jr. announced Thursday clinical trials for the psychedelic drug ibogaine will begin soon following a $4.9 million.

Surfaced by 4 Google Alerts

  • Psychedelics
  • Ibogaine
  • Psychedelic press release
  • Psychedelic crime